靶向心血管炎症:临床转化的下一步
综述总结炎症在动脉粥样硬化性心血管疾病进展、斑块失稳和心肌梗死中的多重作用,指出抗炎治疗临床转化面临挑战,强调炎症程度个体差异大,高敏C反应蛋白(hsCRP)可作为炎症临床指标,未来试验设计纳入hsCRP有望实现个体化治疗。
要点
- 炎症在ASCVD稳定期驱动进展、触发斑块失稳致ACS、并响应心梗后心肌坏死。
- 抗炎治疗临床转化困难,需更个体化策略,因患者炎症程度不同。
- hsCRP是炎症的临床测量指标,未来试验设计纳入hsCRP有望实现个体化。
核心结论
- 靶向炎症防治ASCVD需更个体化方法,未来试验设计纳入hsCRP有望实现正确患者、正确治疗、正确时机。
研究设计与样本
- 临床综述,总结炎症促进ASCVD进展、失稳及不良临床结局的当前认识,并提出未来转化展望。
主要发现
- 全身血管炎症在ASCVD中有多重适应不良作用:驱动稳定期进展、诱发斑块失稳和ACS、响应心梗后心肌坏死。
- 炎症程度在心血管患者中存在差异,成功临床转化具挑战性。
- 大量证据支持hsCRP作为炎症临床测量指标。
临床怎么用
- 认识ACS触发机制的多样性和心梗中hsCRP动力学可能解释既往观察性研究的不一致。
- 未来临床试验设计可纳入hsCRP以支持个体化抗炎策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic vascular inflammation plays multiple maladaptive roles which contribute to the progression and destabilization of atherosclerotic cardiovascular disease (ASCVD). These roles include: (i) driving atheroprogression in the clinically stable phase of disease; (ii) inciting atheroma destabilization and precipitating acute coronary syndromes (ACS); and (iii) responding to cardiomyocyte necrosis in myocardial infarction (MI). Despite an evolving understanding of these biologic processes, successful clinical translation into effective therapies has proven challenging. Realizing the promise of targeting inflammation in the prevention and treatment of ASCVD will likely require more individualized approaches, as the degree of inflammation differs among cardiovascular patients. A large body of evidence has accumulated supporting the use of high-sensitivity C-reactive protein (hsCRP) as a clinical measure of inflammation. Appreciating the mechanistic diversity of ACS triggers and the kinetics of hsCRP in MI may resolve purported inconsistencies from prior observational studies. Future clinical trial designs incorporating hsCRP may hold promise to enable individualized approaches. The aim of this Clinical Review is to summarize the current understanding of how inflammation contributes to ASCVD progression, destabilization, and adverse clinical outcomes. We offer forward-looking perspective on what next steps may enable successful clinical translation into effective therapeutic approaches-enabling targeting the right patients with the right therapy at the right time-on the road to more individualized ASCVD care.
引用
- Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021. PMID: 32176778. doi:10.1093/eurheartj/ehaa099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。